Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FREEDOM COVID Anticoagulation Strategy Randomized Trial
2020-005763-31Phase 2Completed
- Sponsor
- Icahn School of Medicine at Mount Sinai
- Start
- Dec 2020
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised trial in coronavirus disease 2019 (COVID-19) comparing Enoxaparin arm with Apixaban arm (2 arms). Primary endpoint: Composite effectiveness endpoint. Started Dec 2020; status: completed.
02
Drugs
enoxaparinapixaban
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2020-005763-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005763-31.